Dr. Fakhrul Ahsan is a distinguished professor at the
California Northstate University College of Pharmacy (CNUCOP). Before joining
CNUCOP, Dr. Ahsan was a distinguished university professor at Texas Tech
University Health Sciences Center (TTUHSC), wherein he served as a faculty member for 19
years. A pharmacist by training, he earned his pharmacy degree from the
University of Dhaka in Bangladesh. He received his Ph.D. in pharmaceutics from the
Complutense University of Madrid and his postdoctoral training from the
University of Alabama at Birmingham. TTUHSC recognized his excellence as an
educator and investigator by awarding him with the President’s Young
Investigator Award in 2004. His research revolves around developing novel
formulations for the pulmonary delivery of small- and large-molecular-weight
therapeutic agents for treating pulmonary hypertension. He has also been
deploying microfluidic chips for understanding the PAH pathophysiology and
developing diagnostic markers for PAH. His research also involves 3D printing
for customized dosage forms for pediatric PAH patients. He is a member of the
editorial boards of the European Journal of Pharmaceutical Sciences and the
Journal of Pharmacy and Pharmaceutical Sciences and was an Associate Editor of
the Journal of Drug Targeting. Dr. Ahsan is an NIH-funded investigator: he has
received three R15s, two R01 grants, and an R42 grant. He also serves at
various NIH and DoD study sections.
Dr. Fakhrul Ahsan is a distinguished professor at the
California Northstate University College of Pharmacy (CNUCOP). Before joining
CNUCOP, Dr. Ahsan was a distinguished university professor at Texas Tech
University Health Sciences Center (TTUHSC), wherein he served as a faculty member for 19
years. A pharmacist by training, he earned his pharmacy degree from the
University of Dhaka in Bangladesh. He received his Ph.D. in pharmaceutics from the
Complutense University of Madrid and his postdoctoral training from the
University of Alabama at Birmingham. TTUHSC recognized his excellence as an
educator and investigator by awarding him with the President’s Young
Investigator Award in 2004. His research revolves around developing novel
formulations for the pulmonary delivery of small- and large-molecular-weight
therapeutic agents for treating pulmonary hypertension. He has also been
deploying microfluidic chips for understanding the PAH pathophysiology and
developing diagnostic markers for PAH. His research also involves 3D printing
for customized dosage forms for pediatric PAH patients. He is a member of the
editorial boards of the European Journal of Pharmaceutical Sciences and the
Journal of Pharmacy and Pharmaceutical Sciences and was an Associate Editor of
the Journal of Drug Targeting. Dr. Ahsan is an NIH-funded investigator: he has
received three R15s, two R01 grants, and an R42 grant. He also serves at
various NIH and DoD study sections.